Trial intelligence / Profile preview

Degarelix versus goserelin in Chinese patients with prostate cancer

CTR20140109Phase 3Completed

Sponsor
Ferring Pharmaceuticals
Start
May 2014
Modality
Peptides
Countries
1
01

Overview

A Phase 3 trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Started May 2014; status: completed.

02

Drugs

degarelix
03

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on CTR20140109.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20140109.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call